Tech Company Financing Transactions
Cumbre Pharmaceuticals Funding Round
On 3/31/2005, Cumbre Pharmaceuticals raised $10.6 million in investment from Amgen Ventures, private investors and Vulcan Capital.
Transaction Overview
Company Name
Announced On
3/31/2005
Transaction Type
Venture Equity
Amount
$10,589,000
Round
Undisclosed
Investors
Amgen Ventures (Joseph Hagan)
Vulcan Capital (Eric Bell)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
PO Box 191849
Dallas, TX 75219
USA
Dallas, TX 75219
USA
Phone
Website
Email Address
Overview
Cumbre Pharmaceuticals is a research based specialty pharmaceutical company that discovers, develops and markets anti-infective products for the treatment of serious and life-threatening infections, particularly those caused by antibiotic resistant pathogens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bob England
Browse more venture capital transactions:
Prev: 3/31/2005: Integrated Memory Logic venture capital transaction
Next: 3/31/2005: Appfluent Technology venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs